LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.17

+2.1%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$224.65M
EPS-2.8500
P/E Ratio-2.51
Earnings Date07/29/2026

lenz

Accrued Expenses

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Accrued Expenses

LENZ · NASDAQ
CompanyAccrued Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
6.55M
31.2%6.6%10.4%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
3.20M
84.8%40.2%70.9%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.165, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.165